These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31804965)

  • 21. The 10:00-11:00 pm urine cortisol/creatinine ratio. An alternative to late-night salivary cortisol for the diagnosis of Cushing's syndrome.
    Bruno OD; Rossi MA; Juárez-Allen L; Serra HA; Albiero MC
    Medicina (B Aires); 2015; 75(6):373-8. PubMed ID: 26707659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease.
    Amlashi FG; Swearingen B; Faje AT; Nachtigall LB; Miller KK; Klibanski A; Biller BM; Tritos NA
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3770-7. PubMed ID: 26196950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
    Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
    Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
    Feelders RA; Fleseriu M; Kadioglu P; Bex M; González-Devia D; Boguszewski CL; Yavuz DG; Patino H; Pedroncelli AM; Maamari R; Chattopadhyay A; Biller BMK; Pivonello R
    Front Endocrinol (Lausanne); 2023; 14():1165681. PubMed ID: 37876540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desmopressin test in the diagnosis and follow-up of cyclical Cushing's disease.
    Leal-Cerro A; Martín-Rodríguez JF; Ibáñez-Costa A; Madrazo-Atutxa A; Venegas-Moreno E; León-Justel A; García-Hernández N; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
    Endocrinol Nutr; 2014 Feb; 61(2):69-76. PubMed ID: 24183946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specificity of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay for Cushing's disease in an obese population.
    Aberle J; Schulze Zur Wiesch C; Flitsch J; Veigel J; Schön G; Jung R; Reining F; Lautenbach A; Rotermund R; Riedel N
    J Endocrinol Invest; 2018 Nov; 41(11):1325-1331. PubMed ID: 29550934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cushing's Syndrome: Screening and Diagnosis.
    Ceccato F; Boscaro M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):209-15. PubMed ID: 27160717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.
    Trementino L; Zilio M; Marcelli G; Michetti G; Barbot M; Ceccato F; Boscaro M; Scaroni C; Arnaldi G
    Endocrine; 2015 Sep; 50(1):154-61. PubMed ID: 25500791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
    Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
    Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
    Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
    Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Predictors of long-term remission after transsphenoidal surgery in Cushing's disease].
    Abellán Galiana P; Fajardo Montañana C; Riesgo Suárez PA; Gómez Vela J; Escrivá CM; Lillo VR
    Endocrinol Nutr; 2013 Oct; 60(8):475-82. PubMed ID: 23266144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
    Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
    J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes.
    Yaneva M; Mosnier-Pudar H; Dugué MA; Grabar S; Fulla Y; Bertagna X
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3345-51. PubMed ID: 15240613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unpredictable hypersecretion of cortisol in Cushing's disease: detection by daily salivary cortisol measurements.
    Hermus AR; Pieters GF; Borm GF; Verhofstad AA; Smals AG; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1993 May; 128(5):428-32. PubMed ID: 8391195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential role for retinoic acid in patients with Cushing's disease.
    Pecori Giraldi F; Ambrogio AG; Andrioli M; Sanguin F; Karamouzis I; Corsello SM; Scaroni C; Arvat E; Pontecorvi A; Cavagnini F
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3577-83. PubMed ID: 22851491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.
    Barbot M; Guarnotta V; Zilio M; Ceccato F; Ciresi A; Daniele A; Pizzolanti G; Campello E; Frigo AC; Giordano C; Scaroni C
    Endocrine; 2018 Oct; 62(1):207-214. PubMed ID: 29980915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system.
    Carrasco CA; García M; Goycoolea M; Cerda J; Bertherat J; Padilla O; Meza D; Wohllk N; Quiroga T
    Endocrine; 2012 Jun; 41(3):487-93. PubMed ID: 22270871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study.
    Ceccato F; Marcelli G; Martino M; Concettoni C; Brugia M; Trementino L; Michetti G; Arnaldi G
    J Endocrinol Invest; 2019 Mar; 42(3):327-335. PubMed ID: 29987756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.